

12/27/04

Substitute form 1449A/PTO

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet B1 of B1

Application Number 10/651,225  
 Filing Date August 28, 2003  
 First Named Inventor Whittle et al.  
 Group Art Unit 1614  
 Examiner Name  
 Attorney Docket Number 5573-123DV

## U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

## OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
V6	1	Wright, John B., "The Chemistry of the Benzimidazoles," <i>Research Laboratories, The Upjohn Company, Kalamazoo, Michigan</i> , Received January 29, 1951, pages 397-541.	

Examiner Signature Heer Gali Date Considered 06/21/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> <del>09/649,447</del> <b>To Be Assigned</b>	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b> (Use several sheets if necessary)							
Applicants: <span style="float: right;">Whittle et al.</span>							
Filing Date <span style="float: right;">Concurrently</span> <del>August 23, 2000</del> <span style="float: right;">Herewith</span>						Group <del>1743</del>	
U. S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<i>Not related to present application</i>	1.	<del>4,128,658</del>	<del>12/05/78</del>	<del>Price et al.</del>	424	285	
	2.	4,255,431	03/10/81	Junggren et al.	424	263	
	3.	4,279,819	07/21/81	Price et al.	260	326.5 S	
	4.	4,337,257	06/29/82	Junggren et al.	424	263	
	5.	4,508,905	04/02/85	Junggren et al.	546	271	
	6.	4,555,518	11/26/85	Rainer	514	338	
	7.	4,596,795	06/24/86	Pitha	514	58	
	8.	4,612,378	09/16/86	Bosshard et al.	548	170	
	9.	4,620,008	10/28/86	Brändström et al.	546	271	
	10.	4,628,098	12/09/86	Nohara et al.	546	271	
	11.	4,636,499	01/13/87	Brändström et al.	514	222	
	12.	4,725,691	02/16/88	Brändström et al.	546	172	
	13.	4,727,064	02/23/88	Pitha	514	58	
	14.	4,738,974	04/19/88	Brändström	514	338	
	15.	4,753,955	06/28/88	Matsuiishi et al.	514	338	
	16.	4,772,619	09/20/88	Adelstein et al.	514	338	
	17.	4,777,172	10/11/88	Ife et al.	514	234.5	
	18.	4,786,505	11/22/88	Lovgren et al.	424	468	
	19.	4,808,596	02/28/89	Matsuiishi et al.	514	303	
	20.	4,820,708	04/11/89	Ife et al.	514	232.8	
	21.	4,840,799	06/20/89	Appelgren et al.	424	493	
	22.	4,853,230	08/01/89	Lovgren et al.	424	466	
	23.	5,021,443	06/04/91	Bru-Magniez et al.	514	394	
	24.	5,039,806	08/13/91	Brändström et al.	546	271	
	25.	<del>5,045,321</del>	<del>09/03/91</del>	<del>Makino et al.</del>	<del>424</del>	<del>475</del>	

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office  <b>LIST OF DOCUMENTS CITED BY APPLICANT</b>  (Use several sheets if necessary)				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> <del>09/649,447</del>	
				<b>Applicants:</b> Whittle et al.			
				<b>Filing Date</b> August 25, 2000		<b>Group</b> 1743	
<b>U. S. PATENT DOCUMENTS (Cont'd)</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	26.	5,070,101	12/03/91	Kaminski	514	399	
	27.	5,075,323	12/24/91	Fain et al.	514	338	
	28.	5,093,132	03/03/92	Makino et al.	424	475	
	29.	5,093,342	03/03/92	Tomoi et al.	514	328	
	30.	5,096,893	03/17/92	Pitha et al.	514	58	
	31.	5,106,863	04/21/92	Hajos et al.	514	395	
	32.	5,124,158	06/23/92	Ruwart et al.	424	449	
	33.	5,178,867	01/12/93	Guittard et al.	424	473	
	34.	5,196,205	03/23/93	Borody	424	653	
	35.	5,204,118	04/20/93	Goldman et al.	424	489	
	36.	5,206,025	04/27/93	Courteille et al.	424	439	
	37.	5,219,870	06/15/93	Kim	514	338	
	38.	5,232,706	08/03/93	Palomo Coll	424	475	
	39.	5,244,670	09/14/93	Upson et al.	424	439	
	40.	5,246,714	09/21/93	Dahlinder et al.	424	497	
	41.	5,288,506	02/22/94	Spickett et al.	424	498	
	42.	5,294,439	03/15/94	Yamasaka et al.	424	78.01	
	43.	5,294,629	03/15/94	Machinami et al.	514	366	
	44.	5,304,540	04/19/94	Blackburn et al.	514	2	
	45.	5,352,688	10/04/94	Kaminski	514	357	
	46.	5,362,424	11/08/94	Lee et al.	264	4.3	
	47.	5,374,730	12/20/94	Slemon et al.	546	271	
	48.	5,385,739	01/31/95	Debregeas et al.	424	494	
	49.	5,386,032	01/31/95	Brändström	546	271	
	50.	5,391,752	02/21/95	Hoerner et al.	546	271	

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> 09/649,447	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b> (Use several sheets if necessary)							
<b>Applicants:</b> Whittle et al.							
<b>Filing Date</b> August 25, 2000						<b>Group</b> 1743	
<b>U. S. PATENT DOCUMENTS (Cont'd)</b>							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
	51.	5,399,700	05/21/95	Min et al.	546	271	
	52.	5,417,980	05/23/95	Goldman et al.	424	464	
	53.	5,433,959	07/18/95	Makino et al.	424	475	
	54.	5,457,260	10/10/95	Holt	585	820	
	55.	5,476,669	12/19/95	Borody	424	653	
	56.	5,508,041	04/16/96	Leo et al.	424	451	
	57.	5,514,660	05/07/96	Zopf et al.	514	25	
	58.	5,518,730	05/21/96	Fuisz	424	426	
	59.	5,536,735	07/16/96	Takechi et al.	514	338	
	60.	5,569,808	10/29/96	Cansell et al.	585	800	
	61.	5,591,811	11/05/96	Heeres et al.	514	252	
	62.	5,578,732	11/26/96	Kato et al.	546	273.7	
	63.	5,582,837	12/10/96	Shell	424	451	
	64.	5,589,491	12/31/96	Nakanishi et al.	514	338	
	65.	5,599,794	02/04/97	Eek et al.	514	29	
	66.	5,616,593	04/01/97	Patel et al.	514	321	
	67.	5,620,964	04/15/97	Roth et al.	514	53	
	68.	5,622,717	04/22/97	Fuisz	424	488	
	69.	5,629,305	05/13/97	Eek et al.	514	199	
	70.	5,633,244	05/27/97	Eek et al.	514	199	
	71.	5,635,520	06/03/97	Uda	514	338	
	72.	5,637,592	06/10/97	Heeres et al.	514	252	
	73.	5,639,478	06/17/97	Makino et al.	424	475	
	74.	5,639,754	06/17/97	Heeres et al.	514	252	
	75.	5,650,411	07/22/97	Heeres et al.	514	252	

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>LIST OF DOCUMENTS CITED BY APPLICANT</b>  (Use several sheets if necessary)				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> <del>09/649,447</del>	
				<b>Applicants:</b> Whittle et al.			
				<b>Filing Date</b> August 25, 2000		<b>Group</b> 1743	
U. S. PATENT DOCUMENTS (Cont'd)							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<i>Not related</i>	<del>76.</del>	<del>5,651,987</del>	<del>07/29/97</del>	<del>Fuisz</del>	<del>424</del>	<del>488</del>	
	<del>77.</del>	<del>5,656,286</del>	<del>08/12/97</del>	<del>Miranda et al.</del>	<del>424</del>	<del>449</del>	
	<del>78.</del>	<del>5,665,730</del>	<del>09/09/97</del>	<del>Senn-Bilfinger et al.</del>	<del>514</del>	<del>300</del>	
<i>Y6</i>	79.	5,684,580	11/04/97	Cooper et al.	356	301	
	<del>80.</del>	<del>5,686,588</del>	<del>11/11/97</del>	<del>Yoo</del>	<del>536</del>	<del>13.3</del>	
<i>Not related</i>	<del>81.</del>	<del>5,693,818</del>	<del>12/02/97</del>	<del>Von Unge</del>	<del>546</del>	<del>273.7</del>	
	<del>82.</del>	<del>5,710,156</del>	<del>01/20/98</del>	<del>Heeres et al.</del>	<del>514</del>	<del>255</del>	
<i>Y6</i>	83.	5,712,165	01/27/98	Alvarez et al.	436	21	
	<del>84.</del>	<del>5,714,504</del>	<del>02/03/98</del>	<del>Lindberg et al.</del>	<del>514</del>	<del>338</del>	
<i>Not related</i>	<del>85.</del>	<del>5,719,161</del>	<del>02/17/98</del>	<del>Rainer</del>	<del>514</del>	<del>300</del>	
	<del>86.</del>	<del>5,728,700</del>	<del>03/17/98</del>	<del>Heeres et al.</del>	<del>514</del>	<del>252</del>	
<i>Y6</i>	<del>87.</del>	<del>5,731,002</del>	<del>03/24/98</del>	<del>Olovson et al.</del>	<del>424</del>	<del>484</del>	
	88.	5,751,415	05/12/98	Smith et al.	356	301	
<i>Y6</i>	<del>89.</del>	<del>5,753,630</del>	<del>05/19/98</del>	<del>Zopf et al.</del>	<del>514</del>	<del>25</del>	
	90.	5,766,622	06/16/98	Nelson	424	440	
<i>Not related</i>	91.	5,776,765	07/07/98	Graham et al.	435	280	
	<del>92.</del>	<del>5,811,426</del>	<del>09/22/98</del>	<del>Heeres et al.</del>	<del>514</del>	<del>252</del>	
<i>Not related</i>	<del>93.</del>	<del>5,811,547</del>	<del>09/22/98</del>	<del>Nakamichi et al.</del>	<del>540</del>	<del>589</del>	
	<del>94.</del>	<del>5,817,338</del>	<del>10/06/98</del>	<del>Bergstrand et al.</del>	<del>424</del>	<del>468</del>	
<i>Y6</i>	95.	5,840,552	11/24/98	Holt et al.	435	118	
	96.	5,846,562	12/08/98	Yanai et al.	424	451	
<i>Y6</i>	97.	5,859,030	01/12/99	Kohl et al.	514	338	
	<del>98.</del>	<del>5,877,192</del>	<del>03/02/99</del>	<del>Lindberg et al.</del>	<del>514</del>	<del>338</del>	
<i>Y6</i>	99.	5,912,179	06/15/99	Alvarez et al.	436	63	

 EXAMINER  
 \*EXAMINER

*Yell Hale*  
 Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

*06/1/05*

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> <del>09/649,447</del>	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b> (Use several sheets if necessary)							
<b>Applicants:</b> Whittle et al.							
<b>Filing Date</b> August 25, 2000						<b>Group</b> 1743	
<b>U. S. PATENT DOCUMENTS (Cont'd)</b>							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
<i>Not rel Y6 Y6 Y6</i>	<del>100.</del>	<del>5,916,904</del>	<del>06/29/99</del>	<del>Sato et al.</del>	<del>514</del>	<del>338</del>	
	101.	5,929,244	07/27/99	Von Unge	546	273.7	
	<del>102.</del>	<del>5,948,789</del>	<del>09/07/99</del>	<del>Larsson et al.</del>	<del>514</del>	<del>299</del>	
	103.	5,982,484	11/09/99	Clarke et al.	356	301	
	104.	6,100,975	08/08/00	Smith et al.	356	301	
	105.	6,150,380	11/21/00	Lövqvist et al.	514	338	
<b>FOREIGN PATENT DOCUMENTS</b>							
Document Number	Date	Country	Class	Subclass	Translation Yes   No		
106.	0124495 A2	11/07/84	EPO	C07D	401/12	X	
107.	61007281 A2	01/13/86	JAPAN	C07D	513/14	X (Abstract)	
108.	0166287 B1	01/02/86	EPO	C07D	401/12	X	
109.	0171372 A1	02/12/86	EPO	C07D	513/14	X	
110.	61205211	09/11/86	JAPAN	A61K	031/44	X (Abstract)	
111.	0197013 A1	10/08/86	EPO	C07D	401/12	X	
112.	61271259	12/01/86	JAPAN	C07C	93/14	X (Abstract)	
113.	02049774 A2	02/20/90	JAPAN	C07D	235/28	X (Abstract)	
114.	4035455 A1	05/14/92	GERMANY	C07D	401/12	X	
115.	WO 89/03829	05/05/89	WIPO	C07D	401/12	X	
116.	0484265 A1	05/06/92	EPO	C07D	401/12	X	
117.	WO 92/08716	05/29/92	WIPO	C07D	401/12	X (Abstract)	
118.	WO 93/21920	11/11/93	WIPO	A61K	31/44	X	
119.	WO 94/02141	02/03/94	WIPO	A61K	31/44	X	
120.	0585722 A1	03/09/94	EPO	A61K	31/44	X	
121.	06096581	04/08/94	JAPAN	G11C	114/01	X (Abstract)	
122.	06316573	11/15/94	JAPAN	C07D	401/12	X (Abstract)	

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>				<b>Attorney Docket Number</b> 5573-123		<b>Serial No.</b> 09/649,442	
<b>LIST OF DOCUMENTS CITED BY APPLICANT</b> (Use several sheets if necessary)							
<b>Applicants:</b> Whittle et al.							
<b>Filing Date</b> August 25, 2000						<b>Group</b> 1743	
<b>FOREIGN PATENT DOCUMENTS (Cont'd.)</b>							
		Document Number	Date	Country	Class	Subclass	Translation Yes   No
✓	123.	WO 94/27988	12/08/94	WIPO	C07D	401/12	X
✓	124.	WO 95/01783	01/19/95	WIPO	A61K	9/24	X
	125.	WO 95/01977	01/19/95	WIPO	C07D	401/12	X
	126.	WO 95/18612	07/13/95	WIPO	A61K	31/44	X
	127.	WO 95/32957	12/07/95	WIPO	C07D	401/12	X
	128.	WO96/01622	01/25/96	WIPO	A61K	9/24	X
	129.	WO 96/01623	01/25/96	WIPO	A61K	9/26	X
	130.	WO 96/02535	02/01/97	WIPO	C07D	401/12	X
	131.	WO 97/20851	06/12/97	WIPO	C07F	7/08	X
	132.	WO 97/25030	07/17/97	WIPO	A61K	9/46	X
	133.	WO 98/19668	05/14/98	WIPO	A61K	9/50	X
	134.	WO 98/53803	12/03/98	WIPO	A61K	9/28	X
	135.	WO 98/54171	12/03/98	WIPO	C07D	401/12	X
✓	136.	WO 99/08500	02/25/99	WIPO	NONE		X
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
✓	137.	U.S. Patent Application No. 09/519,976 to Whittle et al. entitled <i>Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods of Using the Same</i> ; filed March 7, 2000.					
	138.	U.S. Patent Application No. 09/629,587 to Whittle et al. entitled <i>Pharmaceutical Formulations</i> ; filed July 31, 2000.					
	139.	U.S. Patent Application No. 09/630,022 to Whittle et al. entitled <i>Pharmaceutical Unit Dosage Form</i> ; filed July 31, 2000.					
	140.	U.S. Patent Application No. 09/628,840 to Whittle et al. entitled <i>Method of Improving Bioavailability</i> ; filed July 31, 2000.					
	141.	U.S. Patent Application No. 09/629,634 to Whittle et al. entitled <i>Pharmaceutical Unit Dosage Form</i> ; filed July 31, 2000.					
✓	142.	"The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole," <i>Journal of Medicinal Chemistry</i> 29:8 1327-1329 (1986).					

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>LIST OF DOCUMENTS CITED BY APPLICANT</b>  (Use several sheets if necessary)		<b>Attorney Docket Number</b> 5573-123	<b>Serial No.</b> 09/649,447
		<b>Applicants:</b> Whittle et al.	
		<b>Filing Date</b> August 25, 2000	<b>Group</b> 1743
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) (Cont'd)</b>			
46	143.	Allam et al.; "Molecular interaction of tubulin with 1-deaza-7,8-dihydropteridines: a comparative study of enantiomers NSC 613862 (S) and NSC 613863 (R) by Raman and Fourier transform infrared spectroscopy," <i>Int J Biol Macromol</i> 17:1 55-60 (February 1995).	
	144.	Brändström et al.; "Structure activity relationships of substituted benzimidazoles," <i>Scandinavian Journal of Gastroenterology</i> 20:Supplemental 108 15-22 (1985).	
	145.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. I. A Survey of the Chemical Transformations of Omeprazole and its Analogues," <i>Acta Chemica Scandinavica</i> 43:536-548 (1989).	
	146.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. II. Kinetics of the Reaction of Omeprazole in the Presence of 2-Mercaptoethanol," <i>Acta Chemica Scandinavica</i> 43:549-568 (1989).	
	147.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. III. Protolytic Behaviour of Compounds in the Omeprazole System," <i>Acta Chemica Scandinavica</i> 43:569-576 (1989).	
	148.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. IV. Reactions of Compounds of the Omeprazole System with 2-Mercaptoethanol," <i>Acta Chemica Scandinavica</i> 43:577-586 (1989).	
	149.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. V. The Reaction of N-Alkylated Derivatives of Omeprazole Analogues with 2-Mercaptoethanol," <i>Acta Chemica Scandinavica</i> 43:587-594 (1989).	
	150.	Brändström et al.; "Chemical Reactions of Omeprazole and Omeprazole Analogues. VI. The Reactions of Omeprazole in the Absence of 2-Mercaptoethanol," <i>Acta Chemica Scandinavica</i> 43:595-611 (1989).	
	151.	By et al.; "Fourier transform infrared/Raman differentiation and characterization of cis- and trans-2,5-dimethoxy-4,beta-dimethyl-beta-nitrostyrenes: precursors to the street drug STP," <i>J Forensic Sci</i> 37:2 503-512 (March 1992).	
	152.	By et al.; "4-Hydroxybenzazoles: Preparation and Antibacterial Activities," <i>J. Pharm. and Pharmacol</i> 8:661-665 (1956).	
	153.	Clissold et al.; "Omeprazole A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Peptic Ulcer Disease and Zollinger-Ellison Syndrome," <i>Drugs</i> 32:15-47 (1986).	
	154.	Dluhy et al.; "Infrared characterization of conformational differences in the lamellar phases of 1,3-dipalmitoyl-sn-glycero-2-phosphocholine," <i>Biochim Biophys Acta</i> 821:3 437-444 (Dec. 19, 1985).	
	155.	Erlandsson; "Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a triphenylcarbomoylcellulose-based stationary phase. The effect of the enantiomers of omeprazole on gastric glands," <i>Journal of Chromatography</i> 532:305-319 (1990).	
	156.	Lindberg et al.; "Structure-activity relationships of omeprazole analogues and their mechanism of action," <i>TIPS</i> 8:399-402 (October 1987).	

 EXAMINER  
 \*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>FORM PTO-1449 U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>LIST OF DOCUMENTS CITED BY APPLICANT</b>  (Use several sheets if necessary)		<b>Attorney Docket Number</b> 5573-123	<b>Serial No.</b> 09/649,447
		<b>Applicants:</b> Whittle et al.	
		<b>Filing Date</b> August 25, 2000	<b>Group</b> 1743
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) (Cont'd)</b>			
46	157.	Maier et al.; "Diphenylethanediamine (DPEDA) Derivatives as Chiral Selectors: IV. A Comparison of 3,5-Dinitrobenzoylated (S,S)- and (S,R)-DPEDA-Derived Chiral Stationary Phases with Pirkle's Standard (R)-Phenylglycine-Derived Phase in Normal Phase HPLC," <i>Chirality</i> 6:116-128 (1994).	
	158.	Marle et al.; "Separation of enantiomers using cellulase (CBH I) silica as a chiral stationary phase," <i>Journal of Chromatography</i> 582:233-248 (1991).	
	159.	Marle et al.; "Chiral stationary phases based on intact and fragmented cellobiohydrolase I immobilized on silica," <i>Journal of Chromatography</i> 648:333-347 (1993).	
	160.	Matysik et al.; "Raman spectroscopic analysis of isomers of biliverdin dimethyl ester," <i>J Pharm Biomed Anal</i> 15:9-10 1319-1324 (June 1997).	
	161.	Ohishi et al.; "Structure of 5-Methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole)," <i>Acta Cryst. C</i> 45:1921-1923 (1989).	
	162.	Rudiger et al.; "Reconstitution of bacteriorhodopsin from apoprotein and retinal studied by Fourier-transform infrared spectroscopy," <i>Biochemistry</i> 36:16 4867-4874 (April 22, 1997).	
	163.	Rudolph et al.; "Phase characteristics of positional isomers of 1,2-di(heptacosadiynoyl)-sn-glycero-3-phosphocholine; tubule-forming phosphatidylcholines," <i>Biochim Biophys Acta</i> 943:3 454-462 (September 1, 1988).	
	164.	Sachs et al.; "Gastric H,K-ATPase as Therapeutic Target," <i>Ann. Rev. Pharmacol. Toxicol.</i> 28:269-284 (1988).	
	165.	Uray et al.; "Diphenylethanediamine derivatives as chiral selectors VIII. Influence of the second amido function on the high-performance liquid chromatographic enantioseparation characteristics of (N-3,5-dinitrobenzoyl)-diphenylethanediamine based chiral stationary phases," <i>Journal of Chromatography A</i> 799:1+2 67-81 (March 1998)	
	166.	von Unge et al.; "Stereochemical assignment of the enantiomers of omeprazole from X-ray analysis of a fenchyloxymethyl derivative of (+)-(R)-omeprazole," <i>Tetrahedron: Asymmetry</i> 8:12 1967-1970 (1997).	

 EXAMINER  
 •EXAMINER

Mele Heh

DATE CONSIDERED

08/21/05

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.